OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 12:09:34 03/05/2024 am IST | ||
| 5.06 EUR | +2.85% |
|
| 1 month | +43.02% | ||
| 3 months | +47.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 5.06 | +2.85% | 0 |
| 30/24/30 | 4.92 | +0.20% | 0 |
| 29/24/29 | 4.91 | -0.61% | 0 |
| 26/24/26 | 4.94 | +0.61% | 0 |
| 25/24/25 | 4.91 | +18.89% | 0 |
Delayed Quote Börse Stuttgart
Last update May 03, 2024 at 12:09 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR9TJG |
| ISIN | DE000HR9TJG0 |
| Date issued | 13/09/2021 |
| Strike | 7,803 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.65 € |
|---|---|
| Lowest since issue | 1.25 € |
| Spread | 0.06 € |
| Spread % | 1.18% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.9
USD
Average target price
164.5
USD
Spread / Average Target
+8.29%
- Stock Market
- Certificates
- Certificat
